NICE clears Boehringer's Pradaxa in final appraisal determination
This article was originally published in Scrip
Executive Summary
NICEhas recommended Boehringer Ingelheim's Pradaxa (dabigatran etexilate) for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery. It was approved in the EU in March.
You may also be interested in...
Cerimon receives positive Phase II data on diclofenac patch
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Lilly's Alimta among SMC's September recommendations
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.